Top Markets
#1 DogBull DogBull +105.10%
#2 ADO Protocol ADO Protocol +63.46%
#3 Siacoin Siacoin +44.44%
#4 MarsCoin MarsCoin +37.88%
#5 UnifAI Network UnifAI Network +31.80%
#6 Useless Coin Useless Coin +31.35%
#7 Ontology Gas Ontology Gas +25.74%
#8 Magma Finance Magma Finance +18.63%
#9 Filecoin Filecoin +15.87%
#10 Falcon Finance Falcon Finance +13.91%
Coin of the day
DogBull DogBull
Innstillinger
Språk
NORSK
Valuta
USD
Tema
AbClon Inc. AbClon Inc.

AbClon Inc.

174900
Rangering i aksjer #15851
Founded in Seoul, South Korea, in 2010, AbClon Inc. is a biopharmaceutical... Founded in Seoul, South Korea, in 2010, AbClon Inc. is a biopharmaceutical company engaged in the discovery and development of antibody-based drugs, with operations spanning South Korea and Sweden. The firm's developmental pipeline encompasses therapies derived from distinct technological platforms: the NEST platform addresses breast and gastric cancers; the AffiMab platform targets colon cancer and various autoimmune conditions; and the CAR-T platform is engineered for hematologic and ovarian cancers.
Aksjekurs
$16.42
Markedsverdi
$327.24M
Endring (1 dag)
-3.46%
Endring (1 år)
129.62%
Land
KR
Handel AbClon Inc. (174900)

Kategori

Healthcare
P/S-forhold for AbClon Inc. (174900)
P/S-forhold per 2026 TTM: 0
Ifølge AbClon Inc. sine siste finansielle rapporter og aksjekurs er selskapets nåværende P/S-forhold (TTM) 0. Ved slutten av 2026 hadde selskapet et P/S-forhold på 0.
P/S-historikk for AbClon Inc. fra 2026 til 2026
P/S-forhold ved hvert års slutt
År P/S-forhold Endre
Ikke nok data for de angitte datoene.
P/S-forhold for lignende selskaper eller konkurrenter
Selskap P/S-forhold Forskjell i P/S-forhold Land
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
10.95 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
12.19 -
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
24.99 -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
3.75 -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH